Tighe Wilhelmy with Velawcity here. During this video we will discuss one of the most recent Taxotere litigation updates which came directly from the Judicial Panel on Multi District Litigation, otherwise referred to as the JPML.
The JPML is now allowing claims involving generic chemotherapy drug Docetaxel to be included in the Taxotere MDL in the Eastern District of Louisiana. Sanofi, who manufacturers Taxotere, lost it's patent protection in 2010 and approximately half of the MDL cases include generic manufacturers.
While alopecia is a common side effect of chemotherapy, the claim is that Taxotere is more likely to cause permanent hair loss than the alternative treatments or drugs. In addition, Sanofi-Aventis had been providing such warnings for permanent alopecia to patients and regulatory agencies overseas.
Unfortunatly, claims state that Taxotere's U.S. label was insufficient when warning about permanent alopecia.
The number of pending actions continues to rise. There are about 267 cases filed in the MDL back in December 2016. Where now, there are roughly 1,006 cases filed in the Taxotere MDL.
For more updates like this or to discuss Taxotere case aquisition with us, please feel free to give us a call or visit our website. Again, I'm Tighe Wilhelmy and thanks for watching.